A practical reference on Heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
== Episode 1: Detective Work == Angel Parker is a 23-year-old nursing student. Her earliest memory of her illness dates to when she was 14, and woke in the middle of the night not able to move. Since then her illness has progressed into daily severe muscle pain episodes, where the pain will start at the bottom of her legs and grow its way up to jaw. These episodes render Angel immobile for hours, her pee is pitch black, and very frequently she has to be admitted to the hospital. Angel says that any increase in physical strain or exercise makes her symptoms worse but she still pursues athletic activities. Each time she is admitted, physicians have been unable to find a cause for her pain. She has been tested for Rheumatoid Arthritis, Lupus, Multiple Sclerosis, and Autoimmune diseases - all have had negative results. After a colleague sent Angel’s story to Dr. Lisa Sanders, she decided to take on the case and seek a solution. Dr. Sanders published Angel’s story in her column, Diagnosis, asking readers to help find a diagnosis for her symptoms. One big medical anomaly that physicians have recorded during Angel’s episodes is a rise in her Creatine Kinase levels. Creatine Kinase is muscle protein; Angel's highest CK level recorded during an episode was 57 thousand U/L in comparison to average levels of 22-198 U/L. After Dr. Sanders published Angel’s story, she received thousands of responses on possible diagnosis based on the symptoms.
Dextran hydrogels and dextran conjugate hydrogels are heavily cross-linked polymeric networks that have a strong affinity for water. These gels have soft, elastic physical properties and are biocompatible and biodegradable. Dextran hydrogels have also been shown to be stable and safe in vivo. Glucose-based polymeric gels have the advantage of being able to be chemically or physically modified to improve targeted drug delivery. Swelling is one mechanism by which drugs are released from the dextran hydrogels. Swelling can be reduced by increasing the molecular weight of dextran, leading to a slower drug diffusion rate out of the hydrogel. Swelling can also be lessened by increasing the amount of the conjugated species and introducing ethanol during the cross-linking reaction. Degradation of chemical linkages in the dextran hydrogels is another mechanism by which drugs are released from the polymeric matrices. An increase in degradation of the dextran hydrogel leads to an increase in drug release rate. Degradation of dextran hydrogels specifically is caused by dextranases, which are microbial enzymes mostly located in the colon.
Vitamin E is fat soluble, so dietary supplement products are usually in the form of the vitamin, esterified with acetic acid to generate tocopheryl acetate, and dissolved in vegetable oil in a softgel capsule. For alpha-tocopherol, amounts range from 100 to 1000 IU per serving. Smaller amounts are incorporated into multi-vitamin/mineral tablets. Gamma-tocopherol and tocotrienol supplements are also available from dietary supplement companies. The latter are extracts from palm oil.
Edward Frank Gale. For political service. Richard Gallagher. For services to the community in Aberdeen. Lucy Gannon, Writer. For services to Television Drama. Richard Ian Gardner. For services to the Police. Arthur Buchan Geddes, Sector Officer, the Coastguard Agency, Department of Transport. Arthur Samuel George, School Crossing Patrol, Portsmouth, Hampshire. For services to Road Safety. James Alexander George, Administrative Officer, Ministry of Defence. Graham James Gibb, Leader, Grampian Police and Braemar Mountain Rescue Teams. For services to Mountain Rescue. Alison Gray Gibson, Temporary Project Manager, Royal Mail, Edinburgh. For services to the Post Office. Sydney Gibson, Secretary, Fergusons Lane Tenants Association. For services to the community in Scotswood, Newcastle-upon-Tyne. Valerie Gibson. For services to the Right to Peace and Quiet Campaign. Joan Giddings, lately Office Administrator, British Apparel and Textile Confederation. For services to the Clothing Industry. Elizabeth Glasgow. For services to the community in Wester Hailes, Edinburgh. John Glover. For services to Golf. Maureen Audrey Gobbett, Higher Executive Officer, Ministry of Defence. Major Douglas George Goddard. For services to the community in Wargrave-on-Thames, Berkshire. David William Goodall. For services to Nature Conservation in Hampshire. Ian Kenmure Evans-Gordon. For political service. Stephen Goulding, Pay Band 8, the Employment Service, Department for Education and Employment. Anne Greaves. For services to the Health and Safety Commission's Occupational Health Advisory Committee.
== Stimulants == Stimulants directly affect the central nervous system, increasing blood flow and heart rate. These drugs primarily help athletes in complex team sports like basketball and association football as well as choreographed sports like figure skating and artistic gymnastics. Stimulants that are banned in competition only include amphetamines, beta-2 agonists, ephedrine, pseudoephedrine, fencamfamine, cocaine, methamphetamines, mesocarb, and other substances with similar chemical structures and biological effects, including the following:
Sources: en.wikipedia.org
=== House of Tirol === Albert I (–1078), Count of Eurasburg Albert II (1078–1101), maybe son of Albert I Albert III (1101–1165), son of Albert II Berthold I (1165–1180), son of Albert II Berthold II (1180–1181), son of Berthold I Henry I (1181–1202), son of Berthold I Albert IV (1202–1253), son of Henry I Male line extinct.
Chronic poisoning is long-term repeated or continuous exposure to a poison where symptoms do not occur immediately or after each exposure. The person gradually becomes ill, or becomes ill after a long latent period. Chronic poisoning most commonly occurs following exposure to poisons that bioaccumulate, or are biomagnified, such as mercury, gadolinium, and lead.
The city of Moscow is led by a single mayor, Sergey Sobyanin. The city is divided into 12 administrative okrugs and 125 districts. Moscow's urban planning appeared as early as the 12th century, when the city was founded. The city center grew by amalgamating with suburbs, in keeping with medieval principles of urban development, as strong fortress walls gradually spread along the circular streets of adjacent new settlements. The first circular defense walls established the trajectory for Moscow's rings, laying the groundwork for future city planning. The following fortifications served as the city's circular defense boundaries at some point in history:
== Animal models == Knockout mice of GPX4 die at embryonic day 8 and conditional inducible deletion in adult mice (neurons) results in degeneration and death in less than a month. Targeted disruption of the mitochondrial GPX4 isoform (mGPX4) caused infertility in male mice and disruption of the nuclear GPX4 isoform (nGPX4) reduced the structural stability of sperm chromatin, yet both knockout mouse models (for mGPX4 and nGPX4) were fully viable. Surprisingly, knockout of GPX4 heterozygously in mice (GPX4+/−) increases their median life span. Knockout studies with GPX1, GPX2, or GPX3 deficient mice showed that cytosolic GPX4 is so far the only glutathione peroxidase that is indispensable for embryonic development and cell survival. As mechanisms to dispose of both hydrogen peroxide and lipid hydroperoxides are essential to life, this indicates that in contrast to the multiple metabolic pathways that can be utilized to dispose of hydrogen peroxide, pathways for the disposal of lipid hydroperoxides are limited. While mammals have only one copy of the GPX4 gene, fish have two copies, GPX4a and GPX4b. The GPX4's appear to play a greater role in the fish GPX system than in mammals. For example, in fish GPX4 activity contributes to a greater extent to total GPX activity, GPX4a is the most highly expressed selenoprotein mRNA (in contrast to mammals where it is GPX1 mRNA) and GPX4a appears to be highly inducible to changes within the cellular environment, such as changes in methylmercury and selenium status.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.